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Abstract
Background: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous
system, for which no definitive treatment is available. Most patients start with a relapsing-remitting course (RRMS).
Disease-modifying drugs (DMDs) reduce relapses and disability progression. First line DMDs include glatiramer
acetate (GA), interferon-beta (INFb)-1a and INFb-1b, which are all administered via injections. Effectiveness of DMD
treatment depends on adequate adherence, meaning year-long continuation of injections with a minimum of
missed doses. In real-life practice DMD-treated patients miss 30% of doses. The 6-month discontinuation rate is up
to 27% and most patients who discontinue do so in the first 12 months.
Treatment adherence is influenced by the socio-economic situation, health care and caregivers, disease, treatment
and patient characteristics. Only a few studies have dealt with adherence-related factors in DMD-treated patients.
Self-efficacy expectations were found to be related to GA adherence. Patient education and optimal support
improve adherence in general. Knowledge of the aspects of care that significantly relate to adherence could lead
to adherence-improving measures. Moreover, identification of patients at risk of inadequate adherence could lead
to more efficient care.
In the near future new drugs will become available for RRMS. Detailed knowledge on factors prognostic of
adherence and on care aspects that are associated with adequate adherence will improve the chances of these
drugs becoming effective treatments. We investigate in RRMS patients the relationship between drug adherence
and multidisciplinary care, as well as factors associated with adherence. Given the differences in the frequency of
administration and in the side effects between the DMDs we decided to study patients treated with the same
DMD, GA.
Methods/design: The Correlative analyses of Adherence In Relapsing remitting MS (CAIR) study is an investigator-
initiated, prospective, web-based, patient-centred, nation-wide cohort study in the Netherlands.
The primary objective is to investigate whether GA adherence is associated with specific disciplines of care or
quantities of specific care. The secondary objective is to investigate whether GA adherence is associated with
specific aspects of the socio-economic situation, health care and caregivers, disease, treatment or patient
characteristics.
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All data are acquired on-line via a study website. All RRMS patients in the Netherlands starting GA treatment are
eligible. Patients are informed by neurologists, nurses, and websites from national MS patient organisations. All
data, except on disability, are obtained by patient self-reports on pre-defined and random time points. The number
of missed doses and the number of patients having discontinued GA treatment at 6 and 12 months are measures
of adherence. Per care discipline the number of sessions and the total duration of care are measures of received
care. The full spectrum of non-experimental care that is available in the Netherlands is assessed. Care includes
‘physical’ contacts, contacts by telephone or internet, health-promoting activities and community care activities.
Care received over the preceding 14 days is assessed by patients at baseline and every other week thereafter up to
month 12. Every 3 months neurologists and nurses record care disciplines to which patients have been referred.
The Dutch Adherence Questionnaire-90 (DAQ-90) is a 90-item questionnaire based on the World Health
Organisation (WHO) 2003 report on adherence and comprehensively assesses five domains of evidence-based
determinants of adherence: socio-economic, health care and caregivers, disease, treatment, and patient-related
factors. In addition, self-efficacy is assessed by the MS Self-Efficacy Scale (MSSES), and mood and health-related
quality of life (HRQoL) by the Multiple Sclerosis Quality of Life-54 questionnaire (MSQoL-54). Relapses and adverse
events probably or definitively related to GA are also reported.
Discussion: In this study data is mainly acquired by patients’ self-reporting via the internet. On-line data
acquisition by patients does not require study visits to the hospital and can easily be integrated into daily life. The
web-based nature of the study is believed to prevent missing data and study drop-outs. Moreover, the automated
process of filling in questionnaires ensures completeness and consistency, thus improving data quality. The
combination of patient-reported outcomes, fully web-based data capture and nation-wide information to all
eligible patients are distinguishing features of the study and contribute to its scientific potential.
Trial registration: Netherlands Trial Register (NTR): NTR2432
Background
Multiple sclerosis
Multiple sclerosis (MS) is a chronic inflammatory demye-
linating disease of the central nervous system, for which
no definite cure is available. Most patients start with a
relapsing-remitting (RR) phase during which incomplete
remissions often cause an increase in disability. Glatira-
mer acetate (GA), interferon-beta (INFb)-1a and INFb-1b
are first-line disease-modifying drugs (DMDs) for RRMS
treatment [1], reducing relapses and disability progres-
sion [1]. They are injected subcutaneously (GA every day;
INFb-1a thrice weekly; INFb-1b every other day) or intra-
muscular (INFb-1a once a week). Influenza-like symp-
toms and depression are typical side effects of INFb,
whereas pseudo-anginose symptoms immediately after
injection are specific for GA. Phase 4 studies show that
both INFb-1a [2] and GA treatment [3] are associated
with an increase in HR-QoL. In the long term DMDs
may prevent or delay increase in disability and conver-
sion to secondary progressive MS [4].
Adherence
Adherence to pharmacotherapy is inadequate in 30% to
50% of patients, irrespective of disease, prognosis or
treatment settings [5,6]. Medication for chronic illness is
only taken by 50% to 60% of patients as prescribed [7,8].
There are two levels of inadequate adherence: a) miss-
ing doses and b) discontinuation for other reasons than
severe or persistent side effects or insufficient clinical
benefit [6]. Data on adherence to DMDs in RRMS
patients is scarce. Tremlett et al. found that 1 in 10
patients on DMD missed more than 10 doses in a
6 month period [9]. Missed doses were positively asso-
ciated with alcohol consumption, and a history of
missed doses predicted future missed doses [9]. The
best adherence is reported in low-frequency IFNb, as
compared to high-frequency IFNb or GA [10]. In MS
patients with two or more DMD dispensings the mean
medication possession ratio (MPR) was as low as 68%
for a 24 month period [11].
After 4 months up to 11% of DMD-treated RRMS
patients have discontinued treatment [12], and after
6 months figures vary from 9% to 27% [13]. However, in
MS-specialised academic centres discontinuation rate
was only 1.7% after 6 months and 8% after 2 years [14],
suggesting that adherence may relate to certain qualita-
tive or quantitative aspects of care. Academic MS-cen-
tres provide multidisciplinary care, coordinated by MS-
nurses, whereas care may be more limited in hospitals
without a special interest in MS.
Studies agree that early DMD discontinuation mostly
occurs in the first 12 months [9-11]. Retrospective ana-
lysis of data on GA use in the Netherlands in the period
2003 - 2005 showed a discontinuation rate of 23.9%
within the first year [personal communication by TEVA
Netherlands]. In May 2006 a standard support program,
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Care4MS, was made available to patients starting
GA, delivered by specialised nurses. In the period
2007 - 2009 discontinuation had decreased to 17%
after 12 months [personal communication by TEVA
Netherlands].
Factors relating to adherence
Factors relating to the missing of doses may be different
from those relating to discontinuation [9]. The WHO
2003 report on adherence puts evidence-based factors
into five domains [6]: factors related to 1) the socio-eco-
nomic situation, 2) health care and caregivers, 3) dis-
ease, 4) treatment, and 5) the patient. Only a few
studies dealt with adherence-related factors in DMD
treatment in RRMS [9]. A retrospective study in the U.
S.A. among GA-treated patients identified four variables
as predictors of adherence: self-efficacy, hope, percep-
tion of support, and no previous immunomodulation
[15]. In a prospective study in the U.S.A. pre-treatment
self-efficacy expectations were significantly related to 6-
month adherence [16]. Education and optimal support
of patients starting a DMD are thought to improve
adherence and patient outcomes [17].
A pilot study in the Netherlands assessed 16 patient-
related items that might affect GA adherence: the atti-
tude towards self-injecting, previous immunomodula-
tion, the reason for switching, concurrent chronic
disease, disability, cognition, disease duration, type of
skin, bodily constitution, working in the open, accep-
tance of disease, family support, social activities, person-
ality, motivation and linguistic barrier [unpublished
data]. Scoring each item for presence (1) or absence (0)
the adding up of the scores yields the Discontinuation
Risk Score (DRS), ranging from 0 to 16. Preliminary
data suggest that patients with a DRS > 7 have an
increased risk of GA discontinuation.
Study rationale
According to the WHO 2003 report [6] and a recent
Cochrane Review [18] multidisciplinary interventions
pertaining to factors in all five WHO domains [6] may
improve both levels of adherence. Knowledge on which
qualitative or quantitative aspects of care are associated
with adherence could guide the care given to patients
starting a DMD. Moreover, the determination of factors
prognostic of adherence would enable identification of
patients at risk of inadequate adherence. As a result,
adherence-promoting care could become more effective
and efficient.
At present new DMDs for RRMS are becoming avail-
able. More knowledge on which aspects of multidisci-
plinary care are related to adherence, and the factors
prognostic of inadequate adherence could increase the
chances that the new efficacious drugs become effective
treatments.
We conceived the idea to investigate adherence and
multidisciplinary care in RRMS patients starting DMD
treatment. The INFbs and GA have clearly different side
effect profiles and injection frequencies. As both these
aspects of treatment are likely to influence adherence
we choose to study patients treated with one type of
DMD, thus guaranteeing a homogenous study popula-
tion. Because pilot data on discontinuation and risk fac-
tors were available for GA-treated patients in the
Netherlands, it was decided to study patients starting
GA treatment.
Methods/Design
Objectives
Appendix A lists the questions of the study.
Primary objective is to investigate whether GA adher-
ence is associated with specific disciplines of care or
quantities of specific care.
Secondary objective is to investigate whether GA
adherence is associated with specific characteristics of
socio-economic situation, health care or caregivers, dis-
ease, treatment, or the patient.
Tertiary objective is to assess the predictive value of
the DRS with respect to GA adherence.
Study design and treatment
An investigator-initiated, prospective, web-based,
patient-centred, nation-wide, observational cohort study
in the Netherlands. The study’s name is an acronym
from the principal analytical method, main theme and
study population: Correlative analysis of Adherence In
Relapsing remitting MS: CAIR. The study duration is 12
months. Nederlands Trial Register (NTR) code: TC2432.
GA is prescribed by neurologists as per regular care
and dispensed as a commercial drug by general pharma-
cies (Copaxone®). GA is administered by the patient
according to the instructions in the package leaflet.
Outcomes
Primary outcomes:
a) relations between numbers of missed doses and
numbers of care sessions per discipline s. quantity of
care per discipline,
b) relations between number of patients who discon-
tinued treatment and numbers of care sessions per dis-
cipline s. quantity of care per discipline.
Secondary outcomes:
a) relations between numbers of missed doses and
presence s. degree of specific characteristics of the
patient, socio-economic situation, health care, caregivers,
disease, or treatment,
Jongen et al. BMC Neurology 2011, 11:40
http://www.biomedcentral.com/1471-2377/11/40
Page 3 of 10
b) relations between number of patients who discon-
tinued treatment, and presence s. degree of specific
characteristics of the patient, socio-economic situation,
health care, caregivers, disease, or treatment.
Tertiary outcomes:
a) predictive value of DRS with respect to missed
doses,
a) predictive value of DRS with respect to number of
patients who discontinued treatment.
Patient recruitment
Patients are informed by neurologists, MS-nurses, or
specialised nurses who teach patients to self-inject, and
the websites of patient organisations. Patients are also
advised to visit the study website (http://www.cairstudie.
nl). For further information they may contact the study
helpdesk by telephone or e-mail, or the coordinating
investigator (PJJ) by e-mail.
Recruitment period is from July 2009 to July 2011 and
comprises two phases.
- First phase
In 2009 15 neurological practices with a special interest
in MS care and the respective MS-nurses were recruited
as investigators. Practices were fairly distributed over
the whole country. Since July 2009 they inform patients
starting GA treatment of the possibility of participation
in the study. Objectives and overall requirements are
discussed with the patient. The study information is pre-
ceded by and independent from the decision to start
GA. When a patient decides to participate, the neurolo-
gist or the MS-nurse notifies the helpdesk and participa-
tion is then activated.
- Second phase
Since February 2010 nurses who teach patients to self-
inject briefly inform patients of the study. Patients inter-
ested in receiving further information are handed a
postage paid card addressed to the study helpdesk. On
receipt of the card the helpdesk contacts the patient by
phone and gives information. Patients who, after being
informed, are willing to participate either sign the
informed consent form at their neurologists’ or MS-
nurses’ office or, in case the neurologist is not yet
involved in the study, confirm the text of the informed
consent by clicking on a specific page on the study web-
site. In the latter case the coordinating investigator con-
tacts the neurologist by telephone or e-mail to
introduce the study, and provides the study protocol,
study synopsis and informed consent text. Within two
weeks a second contact is established and the neurolo-
gist informs the coordinating investigator on his/her
decision to participate or not. If the neurologist partici-
pates he/she and the MS-nurse are contacted by the
helpdesk and the site is activated. A negative decision
by the neurologist does not interfere with the patient’s
participation, as the study is patient-centred and the pri-
mary research question may be answered by patient-
derived data only.
Eligibility criteria
Eligibility criteria are minimal.
Inclusion criteria: 1) indication for GA treatment, 2)
being relapse free and having stable symptoms for at
least 30 days, 3) willing and able to comply with the
protocol for the duration of the study, 4) having given
written informed consent.
Exclusion criteria: 1) contra-indication to GA as
defined in the Summary of Product Characteristics text,
2) hypersensitivity to GA or mannitol, 3) worsening of
symptoms suggestive of relapse, 4) pregnancy or lacta-
tion, 5) the time interval between the first GA injection
and baseline assessment is more than 4 weeks.
Ethics
The protocol has been submitted to the Independent
Review Board (IRB), an approved ethical committee
residing in Amsterdam, the Netherlands. The IRB con-
cluded that, because of the observational design of the
study, a review by an ethical committee was not
required, as the study did not qualify for being tested
according to the Dutch Medical Research Involving
Human Subjects Act of 1999 [19].
On-line assessments and measures
Data is acquired via the study website. Patients log in
with a code provided by the help desk and choose a
username and password. On-line they go through var-
ious web pages containing the case record forms (CRFs)
with questions and questionnaires. These electronic
CRFs (eCRFs) are similar to paper questionnaires and
data sheets. Questions relate to missing doses, GA dis-
continuation, adverse events, medication and relapses.
Questionnaires pertain to self-efficacy, mood, other
adherence-related factors and HR-QoL.
Patients, neurologists and MS-nurses are informed by e-
mail that an assessment is due and that the corresponding
eCRFs have been made available for completion. eCRFs
are to be completed within one week. Within this time
frame eCRFs may be filled in at moments that are suitable
to the participant. Completion may take as many sessions
as needed, as answers are saved automatically. After con-
firmation by the participant the eCRF is automatically sent
to the study centre. Incomplete eCRFs are returned. In
case an eCRF has not been completed within one week
the help desk reminds the participant by telephone.
Patients who do not have a personal computer (PC) at
their disposal or who are not capable of using a PC are
sent a paper-and-pencil version of the questionnaires,
whereas short eCRFs are completed by telephone.
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- Adherence
The number of missed doses in the preceding 14 days,
and discontinuation of GA, the date of discontinuation
and the date of restart, which ever is applicable, are
recorded by patients at 3, 6, 9 and 12 months. In addi-
tion, the number of missed doses are documented at 6
random time points unknown to patients, neurologists
and MS-nurses. Neurologist or MS-nurse also record
the date of discontinuation or the date of restart.
- Received care
Care given by the following disciplines is assessed 1)
neurologist, 2) MS-nurse, 3) general practitioner 4)
home care 5) psychologist, 6) occupational therapy, 7)
physiotherapy, 8) social worker, 9) dietician, 10) phar-
macist, 11) rehabilitation doctor, 12) other medical spe-
cialists, 13) community care, 14) others. Care includes
‘physical’ contacts, contacts by telephone, internet,
health-promoting activities that are coached or coun-
selled by caregivers (e.g. medical fitness), or any com-
munity care activities.
Care received in the preceding 14 days is assessed by
patients at baseline and bi-weekly (once every 2 weeks)
thereafter up to week 52. For every discipline in which
care is received, the number of care sessions and time
per care session (in minutes, by approximation) are
recorded. Moreover, every 3 months neurologists and
nurses record the care disciplines to which they have
referred the patient.
- Self-efficacy
Self-efficacy is the subjective belief that one can over-
come challenges that one is faced with, and has been
found to be a determinant of GA adherence in patients
with RRMS [15]. Self-efficacy is assessed by the MS
Self-Efficacy Scale (MSSES). The MSSES is a short, 14-
item, psychometrically validated measure of self-efficacy
specifically for use in people with MS [20]. Each item is
presented with a 6-point Likert scale, ranging from
‘strongly disagree’ to ‘strongly agree’. The MSSES score
ranges from 14-84, a higher score indicating an elevated
level of self-efficacy. The scale has shown sensitivity to
detecting change following a therapeutic intervention.
- Mood and health-related quality of life
Mood is assessed by the questions 25 and 28 from the
Multiple Sclerosis Quality of Life-54 questionnaire
(MSQoL-54) [21]. Health-related quality of life (HR-
QoL) is an overall measure of effectiveness from a
patient’s perspective. The MSQoL-54 is a psychometri-
cally validated MS-specific multi-dimensional inventory
of patient-centered health status. It consists of the 36-
item Short Form (SF-36) health survey as a generic core
measure to enable comparisons to other patient popula-
tions and to the general population, supplemented with
18 additional questions exploring items relevant to
patients with MS [21]. A physical and a mental
dimension underlie the MSQoL-54 [21]. Scores for the
physical and the mental domain range from 0 to 100,
where higher values indicate better HR-QoL.
- Adherence-related factors
The Dutch Adherence Questionnaire-90 (DAQ-90) is a
90-item questionnaire designed to assess all factors
identified by the WHO 2003 report [6] as evidence-
based determinants of adherence (Appendix B). The
DAQ-90 consists of 5 sections corresponding to the five
domains of adherence-related factors in the WHO 2003
report [6]. The DAQ-90 includes questions on hope and
the perception of support and is completed by the
patient at the end of the study.
- Discontinuation Risk Score
At baseline the 16 items of the DRS are scored for
absence (0) or presence (1) by the nurses who teach
patients to self-administer. The adding up of item scores
yields the DRS.
- Adverse events
Adverse events considered by patients, neurologists or
nurses as probably or definitely related to GA treatment
are reported on-line at 3, 6, 9 and 12 months. As the
study is observational and does not interfere with care,
patients always report adverse events to their neurolo-
gist or MS-nurse. Serious adverse events are recorded
by neurologists or MS-nurses and reported to the coor-
dinating investigator within 48 hours.
- Disease characteristics
At baseline neurologists or MS-nurses provide the fol-
lowing data: disease course, disease duration, medica-
tion, previous immunomodulation, the number of
relapses in the last 12 and 24 months, the number of
steroid-treated relapses in the last 12 and 24 months.
Assessment of disability (Expanded Disability Status
Scale [EDSS] score) at baseline and 12 months is
optional. Relapses occurring during the study and even-
tual steroid treatment are reported by patients and neu-
rologists or MS-nurses at months 3, 6, 9 and 12.
Schedule of assessments
The schedule of assessments is presented in Table 1.
Power calculation
In order to determine the size of the study, we first
assumed that the analysis would be based on a t-test: For
each factor we form three tertiles: patients with low, inter-
mediate and high scores. When a t-test is carried out to
compare a parameter between the lowest and highest ter-
tile, 65 patients per tertile are required in order to detect a
difference of 0.5 standard deviations with 80% power (two-
sided alpha = 0.05). As we will use linear regression instead
of a t-test, the power of the regression analysis may even
be higher, but will be at least comparable. In a previous
on-line study in GA-treated patients compliance was very
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high, both with respect to missing data and drop outs [22].
Therefore a total of 200 patients will need to be enrolled.
In phase II of the recruitment all Dutch patients who
start GA treatment are informed of the study. Based on
data from a previous study we hypothesize that 50% of
patients are willing to participate [22]. Based on recent
prescription data it is expected that approximately 300
patients start GA treatment in the Netherlands per year.
So, it is calculated that in phase II recruitment is 150
per year, and that recruitment will end Q2 2011. As per
October 2010, 119 patients have been enrolled.
Statistical analyses
Per discipline the relations between missed doses and the
number of care sessions s. care duration will be evaluated
using linear regression; and the relations between discon-
tinuation and the number of care sessions s. care dura-
tion will be evaluated in a similar way, but by a
proportional hazard analysis, with stepwise selection. In
addition, univariable analyses will be carried out. Two-
sided 95% confidence intervals will be calculated.
Reporting of results
A manuscript, based on the study report, will be sub-
mitted to a peer-reviewed international scientific journal
for publication. Oral or poster communications will be
given on international and national symposia. Participat-
ing patients will receive a summary of the study report
(findings, conclusions), written in a wording that is
understandable to lay persons, as soon as the report has
been finalized.
Discussion
The CAIR study investigates relations between adher-
ence to GA treatment and disciplines or quantity of
care, based on data on missing doses, discontinuation
and received care as reported by patients. Neurologists
or MS-nurses may refer patients to caregivers or give
advice on health promoting activities. However, as
adherence is often sub-optimal in patients with chronic
disease, self-reporting by patients on the care they actu-
ally did receive is likely to better reflect reality [23].
The patient-centred character of the study is realized
by the web-based approach. Data is obtained by the
patient’s on-line self-reporting. Thus, data acquisition
does not require study visits to the hospital and can be
integrated into daily life. This feature of the study is
believed to promote compliance and prevent study
drop-outs. Moreover, the use of the internet contributes
to data quality assurance, as the automated process of
data capture ensures completeness and consistency.
According to the cohort-based, nation-wide design we
aim to inform every RRMS patient in the Netherlands
who starts GA treatment. Neurologists and MS-nurses
in 15 MS-dedicated hospitals, evenly distributed over
the country, actively recruit patients. In addition, the
nurses, who teach patients to self-inject, inform patients
of the possibility of participating. Patients’ awareness of
the study is promoted by information on websites from
national MS patients organisations. Recruitment is on
schedule, with 119 patients being enrolled as per Octo-
ber 2010.
In all, the combination of patient-reported outcomes,
fully on-line data capture, and nation-wide information
of all eligible patients are distinguishing features of the
CAIR study. The nation-wide cohort design makes sure
that results will be applicable to Dutch RRMS patients.
Implementation of the study’s conclusions might well
improve the effectiveness of present and future DMD
treatments, and increase the efficiency of MS care.
Appendix A
List of Questions of the Study
I. What are the relations between GA adherence
and multidisciplinary care?
1. Is the quantity of care given by the neurologist
(number of contacts, total duration of contacts)
related to GA adherence (missed doses,
discontinuation)?
2. Is (the quantity of) care given by the MS-nurse
(number of contacts, total duration of contacts)
related to GA adherence (missed dosed,
discontinuation)?
3. Is (the quantity of care) given by the general prac-
titioner (number of contacts, total duration of con-
tacts) related to GA adherence (missed doses,
discontinuation)?
Table 1 Schedule of assessments
Baseline Month 3 Month 6 Month 9 Month 12
Adherence* X X X X X
MSSES X X
MSQoL-54 X X X
Adverse Events X X X X X
Relapses X X X X X
EDSS** X X
DAQ-90 X
DRS X
*, and at 6 additional random time points.
**, optional.
MSSES, Multiple Sclerosis Self Efficacy Scale.
MSQoL-54, Multiple Sclerosis Quality of Life-54.
EDSS, Expanded Disability Status Scale.
DAQ-90, Dutch Adherence Questionnaire-90.
DRS, Discontinuation Risk Score.
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Table 2 Dutch Adherence Questionnaire-90 (DAQ-90)
I. Algemene/socio-economische omstandigheden
1. Bent u tevreden over uw economische situatie? JA/NEE
2. Vindt u uw besteedbaar maandinkomen voldoende? JA/NEE
3. Bent u voldoende vaardig in schrijven en lezen? JA/NEE
4. Wat is de hoogste afgemaakte opleiding? ..............
5. Was u in het afgelopen jaar (tijdelijk) werkeloos? JA/NEE
6. Had u in het afgelopen jaar deeltijdwerk? JA/NEE
7. Ervaart u voldoende steun van uw sociale netwerken? JA/NEE
8. Zijn uw leefomstandigheden stabiel? JA/NEE
9. Hoever is de afstand tot MS polikliniek/behandelcentrum? ... km
10. Heeft u een eigen bijdrage aan vervoerskosten van - naar polikliniek/behandelcentrum? JA/NEE
11. Heeft u een eigen bijdrage aan medicijnkosten? JA/NEE
12. Is het afgelopen jaar uw leefomgeving veranderd? JA/NEE
13. Waren er het afgelopen jaar gezinsproblemen? JA/NEE/n.v.t.
II. Gezondheidszorg
14. Hoelang duurde het eerste neurologisch consult op deze polikliniek/in dit behandelcentrum? .... min.
15. Hoelang duren gemiddeld de neurologische vervolgconsulten? .... min.
16. Hoelang duurde het eerste MS-verpleegkundig consult op deze polikliniek/in dit behandelcentrum? .... min.
17. Hoelang duren gemiddeld de MS-verpleegkundige vervolgconsulten? .... min.
18. Vindt u de continuïteit van uw MS-zorg voldoende? JA/NEE
19. Is meestal dezelfde neuroloog voor u beschikbaar? JA/NEE
20. Is meestal dezelfde MS-verpleegkundige voor u beschikbaar? JA/NEE
21. Bent u tevreden over de communicatie met uw neuroloog? JA/NEE
22. Bent u tevreden over de communicatie met uw MS-verpleegkundige? JA/NEE
23. Heeft u een goede relatie met uw neuroloog? JA/NEE
24. Heeft u een goede relatie met uw MS-verpleegkundige? JA/NEE
25. Vindt u de kwaliteit van de Nederlandse gezondheidszorg goed ? JA/NEE
26. Worden uw behandelingen en medicijnen volledig vergoed? JA/NEE
27. Wordt Copaxone altijd op tijd geleverd? JA/NEE
28. Hebben de zorgverleners voldoende kennis van MS? JA/NEE
29. Zijn de zorgverleners regelmatig overwerkt? JA/NEE
30. Bent u door de zorgverleners voldoende geïnformeerd over MS? JA/NEE
31. Is met u voldoende besproken hoe u klachten zelf gunstig kunt beïnvloeden? JA/NEE
32. Weet u wat adherentie is? JA/NEE
33. Vindt u adherentie belangrijk? JA/NEE
III. Ziektegerelateerde factoren
34. Heeft u veel last van MS? JA/NEE
35. Heeft u veel beperkingen t.g.v. MS? JA/NEE
36. Is uw MS het afgelopen jaar erg actief geweest? JA/NEE
37. Zijn er volgens u effectieve behandelingen van MS? JA/NEE
38. Kunt u inschatten wat het hebben van MS voor u op termijn kan betekenen? JA/NEE
39. Vindt u Copaxone een adequate behandeling voor uw MS? JA/NEE
40. Heeft u last van depressiviteit? JA/NEE
41. Heeft u andere ziekten behalve MS? JA/NEE
42. Kunt u niet zonder bepaalde geneesmiddelen of bent u afhankelijkheid van bepaalde geneesmiddelen? JA/NEE
43. Bent u verslaafd aan drugs? JA/NEE
44. Bent u afhankelijk van of verslaafd aan alcohol? JA/NEE
45. Hoeveel eenheden alcoholhoudende drank drinkt u per week? per week
IV. Behandelinggerelateerde factoren
46. Indien u behalve Copaxone nog andere medicijnen gebruikt: Heeft u een ingewikkeld schema om alle medicijnen in te
nemen?
JA/NEE/n.v.t.
47. Vindt u behandeling met Copaxone te lang duren? JA/NEE
48. Bent u eerder met interferon gestopt wegens onvoldoende werkzaamheid? JA/NEE
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4. Is (the quantity of) home care (number of con-
tacts, total duration of contacts) related to GA
adherence (missed doses, discontinuation)?
5. Is (the quantity of) care given by a psychologist
(number of contacts, total duration of contacts)
related to GA adherence (missed doses,
discontinuation)?
6. Is (the quantity of) occupational care (number of
contacts, total duration of contacts) related to GA
adherence (missed doses, discontinuation)?
Table 2 Dutch Adherence Questionnaire-90 (DAQ-90) (Continued)
49. Bent u eerder met interferon gestopt wegens bijwerkingen? JA/NEE
50. Heeft u voorafgaande aan Copaxone twee of meer andere middelen gebruikt om terugvallen te voorkomen? JA/NEE
51. Verwachtte u binnen enkele weken gunstige effecten van Copaxone? JA/NEE
52. Ondervond u voldoende ondersteuning om met bijwerkingen om te gaan? JA/NEE
V. Patiëntgerelateerde factoren
53. Vindt u uw kennis en opvattingen over MS adequaat? JA/NEE
54. Bent u gemotiveerd om zelf uw MS te ‘managen’? JA/NEE
55. Heeft u er vertrouwen in dat u uw gedrag/gewoontes kunt veranderen? JA/NEE
56. Heeft u reële verwachtingen t.a.v. het resultaat van Copaxone behandeling? JA/NEE
57. Weet u wat het missen van injecties Copaxone voor u kan betekenen? JA/NEE
58. Heeft u last van vergeetachtigheid? JA/NEE
59. Heeft u last van stress? JA/NEE
60. Bent u bang voor bijwerkingen van Copaxone? JA/NEE
61. Was u bang voor bijwerkingen toen u met Copaxone startte? JA/NEE
62. Heeft u weinig motivatie om Copaxone te spuiten? JA/NEE
63. Had u weinig motivatie toen u met Copaxone startte? JA/NEE
64. Kunt u goed met uw MS klachten omgaan? JA/NEE
65. Kunt u goed uw behandeling zelf ‘managen’? JA/NEE
66. Vindt u de Copaxone behandeling nodig? JA/NEE
67. Merkt u dat Copaxone behandeling effect heeft? JA/NEE
68. Bent u negatief over de werkzaamheid Copaxone? JA/NEE
69. Heeft u MS geaccepteerd? JA/NEE
70. Twijfelt u aan de diagnose MS? JA/NEE
71. Twijfelde u aan de diagnose MS toen u met Copaxone startte? JA/NEE
72. Bent u op de hoogte van de mogelijke risico’s van MS voor uw gezondheid? JA/NEE
73. Bleek achteraf dat u instructies over Copaxone behandeling verkeerd had begrepen? JA/NEE
74. Mist u wel eens een controleafspraak? JA/NEE
75. Heeft u geringe verwachtingen van Copaxone behandeling? JA/NEE
76. Heeft u last van hopeloosheid of negatieve gevoelens? JA/NEE
77. Bent u gefrustreerd over bepaalde zorgverlener(s)? JA/NEE
78. Bent u bang afhankelijk te zijn? JA/NEE
79. Was u bang dat Copaxone uw MS behandeling te ingewikkeld zou maken? JA/NEE
80. Heeft u het gevoel dat u door MS een bepaald stempel heeft gekregen? JA/NEE
81. Was u bezorgd door Copaxone plots uw leefstijl te moeten veranderen? JA/NEE
82. Maakt u zich zorgen over de effecten van Copaxone op lange termijn? JA/NEE
83. Bent u in het algemeen negatief over het gebruik van medicijnen? JA/NEE
84. Vindt u dat artsen in het algemeen teveel medicijnen voorschrijven? JA/NEE
85. Bent u in het algemeen argwanend jegens chemische stoffen in voedsel en milieu? JA/NEE
86. Bent u in het algemeen argwanend jegens wetenschap of technologie? JA/NEE
87. Vindt u het belangrijk dat u met Copaxone wordt behandeld? JA/NEE
88. Had u er bij start van Copaxone vertrouwen in de behandeling te kunnen uitvoeren? JA/NEE
89. Bent u vaak op reis? JA/NEE
90. Heeft u onregelmatige werktijden? JA/NEE
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7. Is (the quantity of) physiotherapy (number of con-
tacts, total duration of contacts) related to GA
adherence (missed doses, discontinuation)?
8. Is (the quantity of) care given by a social worker
(number of contacts, total duration of contacts)
related to GA adherence (missed doses,
discontinuation)?
9. Is (the quantity of) care given by a dietician (num-
ber of contacts, total duration of contacts) related to
GA adherence (missed doses, discontinuation)?
10. Is (the quantity of) care given by the pharmacist
(number of contacts, total duration of contacts) related
to GA adherence (missed doses, discontinuation)?
11. Is (the quantity of) care given by a rehabilitation
doctor (number of contacts, total duration of con-
tacts) related to GA adherence (missed doses,
discontinuation)?
12. Is (the quantity of) community care (number of
contacts, total duration of contacts) related to GA
adherence (missed doses, discontinuation)?
II. What characteristics of the patient, the socio-
economic situation, health care or caregivers, disease,
or treatment are related to GA adherence?
1. Is self-efficacy related to GA adherence?
2. Is mood related to GA adherence?
3. What other characteristics of the patient are
related to GA adherence?
4. What characteristics of the socio-economic situa-
tion, health care or caregivers, disease, or treatment
are related to GA adherence?
III. What is the predictive value of the DRS with
respect to GA adherence?
1. What is the predictive value of the DRS with
respect to GA discontinuation?
2. What is the predictive value of the DRS with
respect to missed GA doses?
Appendix B
Dutch Adherence Questionnaire-90 (DAQ-90) (Table 2)
Based on WHO report 2003
© P.J. Jongen, MS4 Research Institute, Nijmegen, the
Netherlands 2009
Version for Glatiramer Acetate
Patient ID: ........................................................................
Date: ..............................................................................
Study site: ........................................................................
© P.J. Jongen, MS4 Research Institute, Nijmegen, the
Netherlands 2009
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